Drugs / REVDOFILIMAB
REVDOFILIMAB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04196283 | Jan 2020 → Oct 2022 | cancer of unknown primary site | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03818542 | Jan → Sep 2020 | head and neck cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03893955 | May 2019 → Mar 2027 expected | metastatic neoplasm, non-small cell lung carcinoma, triple-negative breast carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03071757 | Mar 2017 → Apr 2022 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REVDOFILIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594516 ↗ |
| Known as | ABBV-368 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03893955 ↗ |
| Known as | PR-1628103 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594516 ↗ |
| Modality | Monoclonal antibody | “ABBV-368 is a humanized monoclonal antibody” PMID 41956545 ↗ Apr 2026 |
| Route | Intravenous | “Intravenous infusion” NCT03071757 ↗ |